ReviewGlobal health & medicine2021
Prevalence, diagnosis, and treatment of hepatitis C in Mainland China.
Review in Global health & medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 47 citations in OpenAlex.
- Pay-it-forward incentives for hepatitis virus testing in men who have sex with men: a cluster randomized trial.Nature medicine · 2023Trial
- Expanding hepatitis C virus test uptake using self-testing among men who have sex with men in China: two parallel randomized controlled trials.BMC medicine · 2023Trial
- Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease.Nature reviews. Gastroenterology & hepatology · 2026Review
- Joinpoint regression and age-period-cohort analyses of global and Chinese acute hepatitis C incidence trends, 1990-2021.Frontiers in public health · 2026Article
- Age-period-cohort and bayesian age-period-cohort prediction modeling of hepatitis C incidence and mortality in China.BMC public health · 2025Article
- NSUN2-mediated HCV RNA m5C Methylation Facilitates Viral RNA Stability and Replication.Genomics, proteomics & bioinformatics · 2025Article
- Analytical performance and standardization of four HCV RNA assays in China: an evaluation of sensitivity, precision, and genotype inclusivity.Frontiers in microbiology · 2025Article
- Time series analysis and scaling law characteristics of viral hepatitis from 2004 to 2023 in Zhejiang Province, China.PloS one · 2025Article
- Awareness of hepatitis C prevention and treatment and high-risk behaviors among the general population in Anhui Province: a cross-sectional study.Frontiers in public health · 2025Article
- Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study.PharmacoEconomics · 2024Article
- HCV RNA positivity among hepatitis C patients in Chongqing, China from 2004 to 2021: a cross-sectional study.BMC infectious diseases · 2024Article
- Hepatitis C virus subtype diversity and transmission clusters characteristics among drug users in Zhuhai, South China.BMC infectious diseases · 2024Article
- Universal screening for HCV infection in China: An effectiveness and cost-effectiveness analysis.JHEP reports : innovation in hepatology · 2024Article
- Hepatitis C Knowledge and Self-Reported Testing Behavior in the General Population in China: Online Cross-Sectional Survey.JMIR public health and surveillance · 2023Article
- Time series analysis-based seasonal autoregressive fractionally integrated moving average to estimate hepatitis B and C epidemics in China.World journal of gastroenterology · 2023Article
- Trends in sexually transmitted and blood-borne infections in China from 2005 to 2021: a joinpoint regression model.BMC infectious diseases · 2023Article
- Trends of Mortality in End-Stage Liver Disease - China, 2008-2020.China CDC weekly · 2023Article
- Periodic Characteristics of Hepatitis Virus Infections From 2013 to 2020 and Their Association With Meteorological Factors in Guangdong, China: Surveillance Study.JMIR public health and surveillance · 2023Article
- Article
- Hepatitis C Prevalence, Incidence, and Treatment in Chinese Hemodialysis Patients: Results From the Dialysis Outcomes and Practice Patterns Study-China (2019-21).Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection with the hepatitis C virus (HCV) is a major cause of liver disease and hepatocellular carcinoma in China. Rapid economic development has had an enormous impact on the epidemiology and treatment of hepatitis C. The prevalence of anti-HCV antibodies in Mainland China is approximately 0.91%, and use of injected drugs has become the main route of HCV transmission in China. Reimbursement for 3 direct-acting antivirals (DAAs) has been approved by the National Medical Insurance scheme in China, which ensures the accessibility of treatment for an HCV infection. To improve the awareness of treatments for hepatitis C among medical personnel and the rate of in-hospital screening for HCV, the Chinese Medical Association has formulated guidelines for the diagnosis and treatment of hepatitis C and a process of in-hospital screening for hepatitis C in China. These efforts have standardized the screening, diagnosis, treatment, and management of hepatitis C. Based on the international strategy for micro-elimination of hepatitis C, China has also screened and treated groups at risk of hepatitis C infection, and this has reduced the number of the infected. The current review describes the status of and issues with the prevalence, diagnosis, and treatment of hepatitis C in Mainland China as part of the global effort to eliminate viral hepatitis by 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.